PMID: 32932644
The split between weightloss and diabetes indications meant carriers and sponsors will need clear criteria on whether to restrict coverage to diabetes (and, if so, under what clinical rules), or to extend support to obesity and cardiometabolic risk reduction more broadly
The only FDA-approved form of recombinant IGF-1 is mecasermin (Increlex), approved in 2005 exclusively for severe primary IGF-1 deficiency in pediatric patients
May Help Decrease Risk of Autoimmune Disease Glutathione is a powerful anti-inflammatory and antioxidant agent
Before starting metformin treatment, tell your doctor if you have a history of allergic reactions to metformin or if you have metabolic acidosis or diabetic ketoacidosis
The ban on coverage for weight-loss treatments was instituted in 2003, partly due to concerns over the safety of fen-phen (the combination of fenfluramine and phentermine), the popular weight loss medication at the time